Fulvestrant binds to the estrogen receptors on cancer cells, altering their shape and function. This leads to the degradation of the receptors, ultimately reducing the ability of estrogen to stimulate the growth of breast cancer cells. By targeting the estrogen receptor directly, fulvestrant effectively disrupts the signaling pathways that promote tumor growth.
